<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ABELCET- amphotericin b, dimyristoylphosphatidylcholine, dl- and dimyristoylphosphatidylglycerol, dl- injection </strong><br>Sigma-Tau Pharmaceuticals, Inc.<br></p></div>
<h1><span class="Bold">ABELCET® (Amphotericin B Lipid Complex Injection) 100 mg</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_368a5f96-0ed5-49ad-ac23-4fe82ceb3cd6"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ABELCET<span class="Sup">®</span> is a sterile, pyrogen-free suspension for intravenous infusion. ABELCET<span class="Sup">®</span> consists of amphotericin B complexed with two phospholipids in a 1:1 drug-to-lipid molar ratio. The two phospholipids, l-α-dimyristoylphosphatidylcholine (DMPC) and l-α-dimyristoylphosphatidylglycerol (DMPG), are present in a 7:3 molar ratio. ABELCET<span class="Sup">®</span> is yellow and opaque in appearance, with a pH of 5 - 7. </p>
<p><span class="Bold">NOTE: Liposomal encapsulation or incorporation in a lipid complex can substantially affect  a drug’s functional properties relative to those of the unencapsulated or nonlipid-associated drug. In addition, different liposomal or lipid-complexed products with a common active ingredient may vary from one another in the chemical composition and physical form of the lipid component. Such differences may affect functional properties of these drug products.</span></p>
<p>Amphotericin B is a polyene, antifungal antibiotic produced from a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Streptomyces nodosus</span>. Amphotericin B is designated chemically as [1R-(1R*, 3S*, 5R*, 6R*, 9R*, 11R*, 15S*, 16R*, 17R*, 18S*, 19E, 21E, 23E, 25E, 27E, 29E, 31E, 33R*, 35S*, 36R*, 37S*)]-33-[(3-Amino-3, 6-dideoxy- β-D-mannopyranosyl) oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1] nonatriaconta-19, 21, 23, 25, 27, 29, 31-heptaene-36-carboxylic acid. </p>
<p>It has a molecular weight of 924.09 and a molecular formula of C<span class="Sub">47</span>H<span class="Sub">73</span>NO<span class="Sub">17</span>. The structural formula is: </p>
<div class="Figure">
<a name="id237"></a><img alt="chemical image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5587db37-f21a-4a39-a319-e1077032ced9&amp;name=b0ed110c-f86e-4dd7-87eb-afe9ed042c69-01.jpg">
</div>
<p>ABELCET<span class="Sup">®</span> is provided as a sterile, opaque suspension in 20 mL glass, single-use vials. Each 20 mL vial contains 100 mg of amphotericin B (see DOSAGE AND ADMINISTRATION), and each mL of ABELCET<span class="Sup">®</span> contains: </p>
<p>Amphotericin B USP 5.0 mg</p>
<p>l-α-dimyristoylphosphatidylcholine (DMPC) 3.4 mg</p>
<p>l-α-dimyristoylphosphatidylglycerol (DMPG) 1.5 mg</p>
<p>Sodium Chloride USP 9.0 mg</p>
<p>Water for Injection USP, q.s. 1 mL</p>
<p><span class="Bold">MICROBIOLOGY</span></p>
<p><span class="Bold">Mechanism of Action</span></p>
<p>The active component of ABELCET<span class="Sup">®</span>, amphotericin B, acts by binding to sterols in the cell membrane of susceptible fungi, with a resultant change in the permeability of the membrane. Mammalian cell membranes also contain sterols, and damage to human cells is believed to occur through the same mechanism of action. </p>
<p><span class="Bold">Activity <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span></span></p>
<p>ABELCET<span class="Sup">®</span> shows in vitro activity against <span class="Italics">Aspergillus</span> sp. (n=3) and <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> sp. (n=10), with MICs generally &lt;1 μg/mL. Depending upon the species and <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Aspergillus</span> and <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> tested, significant <span class="Italics">in vitro</span> differences in susceptibility to amphotericin B have been reported (MICs ranging from 0.1 to &gt;10 mg/mL). However, standardized techniques for susceptibility testing for antifungal agents have not been established, and results of susceptibility studies do not necessarily correlate with clinical outcome.</p>
<p>ABELCET<span class="Sup">®</span> is active in animal models against <span class="Italics">Aspergillus fumigatus, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans, C. guillermondii, C. stellatoideae</span>, and <span class="Italics">C. tropicalis, Cryptococcus</span> sp., <span class="Italics">Coccidioidomyces</span> sp., <span class="Italics">Histoplasma</span> sp., and <span class="Italics">Blastomyces </span>sp. in which end-points were clearance of microorganisms from target organ(s) and/or prolonged survival of infected animals. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></span></p>
<p>Fungal species with decreased susceptibility to amphotericin B have been isolated after serial passage in culture media containing the drug, and from some patients receiving prolonged therapy. Although the relevance of <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> to clinical outcome has not been established, fungal species which are resistant to amphotericin B may also be resistant to ABELCET<span class="Sup">®</span>.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f2440dc0-3820-4343-8325-459e4556c53a"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><span class="Bold">Pharmacokinetics</span></p>
<p>The assay used to measure amphotericin B in the blood after the administration of ABELCET<span class="Sup">®</span> does not distinguish amphotericin B that is complexed with the phospholipids of ABELCET<span class="Sup">®</span> from amphotericin B that is uncomplexed.</p>
<p>The pharmacokinetics of amphotericin B after the administration of ABELCET<span class="Sup">®</span> are nonlinear. Volume of distribution and clearance from blood increase with increasing dose of ABELCET<span class="Sup">®</span>, resulting in less than proportional increases in blood concentrations of amphotericin B over a dose range of 0.6-5 mg/kg/day. The pharmacokinetics of amphotericin B in whole blood after the administration of ABELCET<span class="Sup">®</span> and amphotericin B desoxycholate are:</p>
<table width="100%">
<col width="40%">
<col width="27%">
<col width="33%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="3">
<p class="First"><span class="Bold">Pharmacokinetic Parameters of Amphotericin B in Whole Blood </span></p>
<p><span class="Bold">in Patients Administered Multiple Doses of ABELCET<span class="Sup">®</span> or Amphotericin B Desoxycholate</span></p>
</td></tr>
<tr>
<td class="Lrule"><p class="First"><span class="Bold">Pharmacokinetic Parameter</span></p></td>
<td align="center"><p class="First"><span class="Bold">ABELCET<span class="Sup">® </span>5 mg/kg/day for 5-7 days Mean ± SD</span></p></td>
<td class="Rrule" align="center"><p class="First"><span class="Bold">Amphotericin B</span><br><span class="Bold">0.6 mg/kg/day for 42 days<span class="Sup">a </span> Mean ± SD</span></p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Peak Concentration ( μg/mL)</p></td>
<td align="center"><p class="First"> 1.7 ±  0.8 (n=10)<span class="Sup">b</span></p></td>
<td class="Rrule" align="center"><p class="First">  1.1 ±    0.2 (n=5)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Concentration at End of Dosing Interval (μg/mL)</p></td>
<td align="center"><p class="First"> 0.6 ±  0.3 (n=10<span class="Sup">b</span></p></td>
<td class="Rrule" align="center"><p class="First">  0.4 ±    0.2 (n=5)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Area Under Blood Concentration-Time Curve <br>  (AUC<span class="Sub">0-24h</span>) (μg*h/mL)</p></td>
<td align="center"><p class="First"><br> 14.0 ± 7.0 (n=14)<span class="Sup">b,c</span></p></td>
<td class="Rrule" align="center"><p class="First"><br> 17.1 ±    5    (n=5)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Clearance (mL/h*kg)</p></td>
<td align="center"><p class="First"> 436.0.± 188.5 (n=14)<span class="Sup">b,c</span></p></td>
<td class="Rrule" align="center"><p class="First"> 38.0 ±  15    (n=5)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Apparent Volume of Distribution (Vd<span class="Sub">area</span>) (L/kg)</p></td>
<td align="center"><p class="First"> 131.0.±  57.7 (n=8)<span class="Sup">c</span></p></td>
<td class="Rrule" align="center"><p class="First"> 5.0.±    2.8 (n=5)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Terminal Elimination Half-Life (h)</p></td>
<td align="center"><p class="First"> 173.4 ± 78.0 (n=8)<span class="Sup">c</span></p></td>
<td class="Rrule" align="center"><p class="First"> 91.1 ±  40.9 (n=5)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Amount Excreted in Urine Over 24 h After Last Dose (% of dose)<span class="Sup">d</span></p></td>
<td class="Botrule" align="center"><p class="First"><br> 0.9 ± 0.4 (n=8)<span class="Sup">c</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><br> 9.6 ±    2.5 (n=8)</p></td>
</tr>
</tbody>
</table>
<p> <span class="Sup">a</span> Data from patients with mucocutaneous leishmaniasis. Infusion rate was 0.25 mg/kg/h.</p>
<p><span class="Sup">b</span> Data from studies in patients with cytologically proven cancer being treated with chemotherapy or neutropenic patients with <br>  presumed or proven <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>. Infusion rate was 2.5 mg/kg/h.</p>
<p><span class="Sup">c</span> Data from patients with mucocutaneous leishmaniasis. Infusion rate was 4 mg/kg/h.</p>
<p><span class="Sup">d</span> Percentage of dose excreted in 24 hours after last dose.</p>
<p>The large volume of distribution and high clearance from blood of amphotericin B after the admistration of ABELCET<span class="Sup">®</span> probably reflect uptake by tissues. The long terminal elimination half-life probably reflects a slow redistribution from tissues. Although amphotericin B is excreted slowly, there is little accumulation in the blood after repeated dosing. AUC of amphotericin B increased approximately 34% from day 1 after the administration of ABELCET<span class="Sup">®</span> 5 mg/kg/day for 7 days. The effect of gender or ethnicity on the pharmacokinetics of ABELCET<span class="Sup">®</span> has not been studied.</p>
<p>Tissue concentrations of amphotericin B have been obtained at autopsy from one heart transplant patient who received three doses of ABELCET<span class="Sup">®</span> at 5.3 mg/kg/day:</p>
<table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Concentration in Human Tissues</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><br><span class="Bold">Organ</span></p></td>
<td class="Botrule Rrule" align="center">
<p class="First"><span class="Bold">Amphotericin B</span></p>
<p><span class="Bold">Tissue Concentration (µg/g)</span></p>
</td>
</tr>
<tr>
<td class="Lrule"><p class="First"> Spleen</p></td>
<td class="Rrule" align="center"><p class="First">290.0</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"> Lung</p></td>
<td class="Rrule" align="center"><p class="First">222.0</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"> Liver</p></td>
<td class="Rrule" align="center"><p class="First">196.0</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"> Lymph Node</p></td>
<td class="Rrule" align="center"><p class="First">   7.6</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"> Kidney</p></td>
<td class="Rrule" align="center"><p class="First">  6.9</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"> Heart 0</p></td>
<td class="Rrule" align="center"><p class="First">5.</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"> Brain</p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 1.6</p></td>
</tr>
</tbody>
</table>
<p> This pattern of distribution is consistent with that observed in preclinical studies in dogs in which greatest concentrations of amphotericin B after ABELCET<span class="Sup">®</span> administration were observed in the liver, spleen, and lung; however, the relationship of tissue concentrations of amphotericin B to its biological activity when administered as ABELCET<span class="Sup">®</span> is unknown.</p>
<p><span class="Bold">Special Populations</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the disposition of ABELCET<span class="Sup">®</span> is not known.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the disposition of ABELCET<span class="Sup">®</span> is not known. The effect of dialysis on the elimination of ABELCET<span class="Sup">®</span> has not been studied; however, amphotericin B is not removed by hemodialysis when administered as amphotericin B desoxycholate.</p>
<p><span class="Italics">Pediatric and Elderly Patients: </span> The pharmacokinetics and pharmacodynamics of pediatric patients (≤16 years of age) and elderly patients (≥65 years of age) have not been studied.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_4f212cd0-18b4-4fb3-b392-a01f50241b4a"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ABELCET<span class="Sup">®</span> is indicated for the treatment of invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> in patients who are refractory to or intolerant of conventional amphotericin B therapy. This is based on open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin B therapy (See DESCRIPTION OF CLINICAL STUDIES).  </p>
<p><span class="Bold">DESCRIPTION OF CLINICAL STUDIES</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infections</span></span></p>
<p>Data from 473 patients were pooled from three open-label studies in which ABELCET<span class="Sup">®</span> was provided for the treatment of patients with invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> who were judged by their physicians to be refractory to or intolerant of conventional amphotericin B, or who had preexisting <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. Results of these studies demonstrated effectiveness of ABELCET<span class="Sup">®</span> in the treatment of invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> as a second line therapy.</p>
<p> Patients were defined by their individual physician as being refractory to or failing conventional amphotericin B therapy based on overall clinical judgement after receiving a minimum total dose of 500 mg of amphotericin B. <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> was defined as a serum creatinine that had increased to &gt;2.5 mg/dL in adults and &gt;1.5 mg/dL in pediatric patients, or a creatinine clearance of &lt;25 mL/min while receiving conventional amphotericin B therapy.</p>
<p> Of the 473 patients, four were enrolled more than once; each enrollment contributed separately to the denominator. The median age was 39 years (range of &lt;1 to 93 years); 307 patients were male and 166 female. Patients were Caucasian (381, 81%), African-American (41, 9%), Hispanic (27, 6%), Asian (10, 2%), and various other races (14, 3%). The median baseline neutrophil count was 4,000 PMN/mm3; of these, 101 (21%) had a baseline neutrophil count &lt;500/mm<span class="Sup">3</span>.</p>
<p> Two-hundred eighty-two patients of the 473 patients were considered evaluable for response to therapy; the other 191 patients were excluded on the basis of unconfirmed diagnosis, confounding factors, concomitant systemic antifungal therapy, or receiving 4 doses or less of ABELCET<span class="Sup">®</span>. For evaluable patients, the following <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> were treated (n=282): <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> (n=111), <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> (n=87), zygomycosis (n=25), <span class="product-label-link" type="condition" conceptid="440035" conceptname="Cryptococcosis">cryptococcosis</span> (n=16), and fusariosis (n=11). There were fewer than 10 evaluable patients for each of several other fungal species treated.</p>
<p> For each type of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> listed above there were some patients successfully treated. However, in the absence of controlled studies it is unknown how response would have compared to either continuing conventional amphotericin B therapy or the use of alternative antifungal agents.</p>
<p><span class="Bold">Renal Function:</span> Patients with <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> who initiated treatment with ABELCET<span class="Sup">®</span> when serum creatinine was above 2.5 mg/dL experienced a decline in serum creatinine during treatment (Figure 1). Serum creatinine levels were also lower during treatment with ABELCET<span class="Sup">®</span> when compared to the serum creatinine levels of patients treated with conventional amphotericin B in a retrospective historical control study. Meaningful statistical testing of the differences between these two groups is precluded since these data were obtained from two separate studies. </p>
<div class="Figure">
<a name="id450"></a><img alt="figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5587db37-f21a-4a39-a319-e1077032ced9&amp;name=b0ed110c-f86e-4dd7-87eb-afe9ed042c69-02.jpg">
</div>
<p><span class="Bold">[ ]= Number of patients at each time point.</span></p>
<p>Note: These curves do not represent the clinical course of a given patient, but that of an open-label cohort of patients.</p>
<div class="Figure">
<a name="id454"></a><img alt="figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5587db37-f21a-4a39-a319-e1077032ced9&amp;name=b0ed110c-f86e-4dd7-87eb-afe9ed042c69-03.jpg">
</div>
<p><span class="Bold">[ ]= Number of patients at each time point.</span></p>
<p>Note: These curves do not represent the clinical course of a given patient, but that of an open-label cohort of patients.</p>
<p>In a randomized study of ABELCET<span class="Sup">®</span> for the treatment of <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">invasive candidiasis</span> in patients with normal baseline renal function, the incidence of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> was significantly less for ABELCET<span class="Sup">®</span> at a dose of 5 mg/kg/day than for conventional amphotericin B at a dose of 0.7 mg/kg/day.</p>
<p>Despite generally less <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> of ABELCET<span class="Sup">®</span> observed at a dose of 5 mg/kg/day compared with conventional amphotericin B therapy at a dose range of 0.6-1 mg/kg/day, dose-limiting renal toxicity may still be observed with ABELCET<span class="Sup">®</span>. Renal toxicity of doses greater than 5 mg/kg/day of ABELCET<span class="Sup">®</span> has not been formally studied.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_9d1f3d2a-b149-4bd4-97a4-36c290b2b805"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ABELCET<span class="Sup">®</span> is contraindicated in patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to amphotericin B or any other component in the formulation.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_9e124c19-8322-4212-b8da-3362161608b1"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has been reported with amphotericin B desoxycholate and other amphotericin B-containing drugs. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has been reported with ABELCET<span class="Sup">®</span> with an incidence rate of &lt;0.1%. If severe <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> occurs, the infusion should be immediately discontinued. The patient should not receive further infusions of ABELCET<span class="Sup">®</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_86642059-7840-434c-b4c7-20c7489a9c8d"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_0fcc5e5b-a062-4c53-930d-542146e2876a"></a><a name="section-6.1"></a><p></p>
<h2>General: </h2>
<p class="First">As with any amphotericin B-containing product, during the initial dosing of ABELCET<span class="Sup">®</span>, the drug should be administered under close clinical observation by medically trained personnel.</p>
<p>Acute reactions including <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> may occur 1 to 2 hours after starting an intravenous infusion of ABELCET<span class="Sup">®</span>. These reactions are usually more common with the first few doses of ABELCET<span class="Sup">®</span> and generally diminish with subsequent doses. Infusion has been rarely associated with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_13c17b22-44bb-4bfd-b3d3-e74c9119a88b"></a><a name="section-6.2"></a><p></p>
<h2>Laboratory Tests:</h2>
<p class="First">Serum creatinine should be monitored frequently during ABELCET<span class="Sup">®</span> therapy (see ADVERSE REACTIONS). It is also advisable to regularly monitor liver function, serum electrolytes (particularly magnesium and potassium), and complete blood counts. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_392e7c31-a9f6-4d63-81db-dc6a1bf178c4"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions: </h2>
<p class="First">No formal clinical studies of drug interactions have been conducted with ABELCET<span class="Sup">®</span>. However, when administered concomitantly, the following drugs are known to interact with amphotericin B; therefore, the following drugs may interact with ABELCET<span class="Sup">®</span>: </p>
<p><span class="Italics">Antineoplastic agents: </span>Concurrent use of antineoplastic agents and amphotericin B may enhance the potential for renal toxicity, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Antineoplastic agents should be given concomitantly with ABELCET<span class="Sup">®</span> with great caution.</p>
<p><span class="Italics">Corticosteroids and corticotropin (ACTH): </span>Concurrent use of corticosteroids and corticotropin (ACTH) with amphotericin B may potentiate <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> which could predispose the patient to cardiac dysfunction. If used concomitantly with ABELCET<span class="Sup">®</span>, serum electrolytes and cardiac function should be closely monitored.</p>
<p><span class="Italics">Cyclosporin A: </span>Data from a prospective study of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> ABELCET<span class="Sup">®</span> in 22 patients undergoing bone marrow transplantation suggested that concurrent initiation of cyclosporin A and ABELCET<span class="Sup">®</span> within several days of bone marrow ablation may be associated with increased <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. </p>
<p><span class="Italics">Digitalis glycosides: </span>Concurrent use of amphotericin B may induce <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and may potentiate <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>. When administered concomitantly with ABELCET<span class="Sup">®</span>, serum potassium levels should be closely monitored.</p>
<p><span class="Italics">Flucytosine</span>: Concurrent use of flucytosine with amphotericin B-containing preparations may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion. Flucytosine should be given concomitantly with ABELCET<span class="Sup">®</span> with caution.      </p>
<p><span class="Italics">Imidazoles (e.g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): </span>Antagonism between amphotericin B and imidazole derivatives such as miconazole and ketoconazole, which inhibit ergosterol synthesis, has been reported in both in vitro and in vivo animal studies. The clinical significance of these findings has not been determined.      </p>
<p><span class="Italics">Leukocyte transfusions: </span>Acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions. Leukocyte transfusions and ABELCET<span class="Sup">®</span> should not be given concurrently.</p>
<p><span class="Italics">Other nephrotoxic medications</span>: Concurrent use of amphotericin B and agents such as aminoglcosides and pentamidine may enhance the potential for drug-induced renal toxicity. Aminoglycosides and pentamidine should be used concomitantly with ABELCET<span class="Sup">®</span> only with great caution. Intensive monitoring of renal function is recommended in patients requiring any combination of nephrotoxic medications.</p>
<p><span class="Italics">Skeletal muscle relaxants:</span> Amphotericin B-induced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine) due to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. When administered concomitantly with ABELCET<span class="Sup">®</span>, serum potassium levels should be closely monitored.</p>
<p><span class="Italics">Zidovudine:</span> Increased myelotoxicity and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> were observed in dogs when either ABELCET<span class="Sup">®</span> (at doses 0.16 or 0.5 times the recommended human dose) or amphotericin B desoxycholate (at 0.5 times the recommended human dose) were administered concomitantly with zidovudine for 30 days. If zidovudine is used concomitantly with ABELCET<span class="Sup">®</span>, renal and hematologic function should be closely monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1a17074d-0975-4595-8be9-4078fccd7698"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility: </h2>
<p class="First">No long-term studies in animals have been performed to evaluate the carcinogenic potential of ABELCET<span class="Sup">®</span>. The following <span class="Italics">in vitro</span> (with and without metabolic activation) and <span class="Italics">in vivo</span> studies to assess ABELCET<span class="Sup">®</span> for mutagenic potential were conducted: bacterial reverse mutation assay, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> forward mutation assay, chromosomal aberration assay in CHO cells, and <span class="Italics">in vivo</span> mouse micronucleus assay. ABELCET<span class="Sup">®</span> was found to be without mutagenic effects in all assay systems. Studies demonstrated that ABELCET<span class="Sup">®</span> had no impact on fertility in male and female rats at doses up to 0.32 times the recommended human dose (based on body surface area considerations). </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_de814feb-8ce4-4bbd-9ccb-3e3a8966a427"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy: </h2>
<p class="First">There are no reports of pregnant women having been treated with ABELCET<span class="Sup">®</span>. Teratogenic Effects. Pregnancy Category B: Reproductive studies in rats and rabbits at doses of ABELCET<span class="Sup">®</span> up to 0.64 times the human dose revealed no harm to the fetus. Because animal reproductive studies are not always predictive of human response, and adequate and well-controlled studies have not been conducted in pregnant women, ABELCET<span class="Sup">®</span> should be used during pregnancy only after taking into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_d2f7a90b-5715-4186-9e86-60eb37849109"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers: </h2>
<p class="First">It is not known whether ABELCET<span class="Sup">®</span> is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in breast-fed infants from ABELCET<span class="Sup">®</span>, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_393d1f26-255d-4ce1-8fe9-1c6357bc1319"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use: </h2>
<p class="First">One hundred eleven children (2 were enrolled twice and counted as separate patients), age 16 years and under, of whom 11 were less than 1 year, have been treated with ABELCET<span class="Sup">®</span>  at 5 mg/kg/day in two open-label studies and one small, prospective, single-arm study. In one single-center study, 5 children with hepatosplenic <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> were effectively treated with 2.5 mg/kg/day of ABELCET<span class="Sup">®</span>. No serious unexpected adverse events have been reported. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_8f51c579-3cbb-429c-85ce-7b41aa986cdf"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric Use: </h2>
<p class="First">Forty-nine elderly patients, age 65 years or over, have been treated with ABELCET<span class="Sup">®</span> at 5 mg/kg/day in two open-label studies and one small, prospective, single-arm study. No serious unexpected adverse events have been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_b462a29e-93c0-4631-9918-4cf7a6b0b2cc"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The total safety data base is composed of 921 patients treated with ABELCET<span class="Sup">®</span> (5 patients were enrolled twice and counted as separate patients), of whom 775 were treated with 5 mg/kg/day. Of these 775 patients, 194 patients were treated in four comparative studies; 25 were treated in open-label, non-comparative studies; and 556 patients were treated in an open-label, emergency-use program. Most had underlying hematologic neoplasms, and many were receiving multiple concomitant medications. Of the 556 patients treated with ABELCET<span class="Sup">®</span>, 9% discontinued treatment due to adverse events regardless of presumed relationship to study drug.</p>
<p>    In general, the adverse events most commonly reported with ABELCET<span class="Sup">®</span> were transient <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and/or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> during infusion of the drug. </p>
<table width="100%">
<col width="42%">
<col width="58%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Adverse Events<span class="Sup">a</span> with an Incidence of ≥3% (N=556)</span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Adverse Event</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Percentage (%) of Patients</span></p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></p></td>
<td class="Rrule" align="center"><p class="First"> 18</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td class="Rrule" align="center"><p class="First"> 14</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Increased Serum Creatinine</p></td>
<td class="Rrule" align="center"><p class="First"> 11</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4212484" conceptname="Multiple organ failure">Multiple Organ Failure</span></p></td>
<td class="Rrule" align="center"><p class="First"> 11</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Rrule" align="center"><p class="First"> 9</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p></td>
<td class="Rrule" align="center"><p class="First"> 8</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">Respiratory Failure</span></p></td>
<td class="Rrule" align="center"><p class="First"> 8</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Rrule" align="center"><p class="First"> 8</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Rrule" align="center"><p class="First"> 7</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span></p></td>
<td class="Rrule" align="center"><p class="First"> 7</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Rrule" align="center"><p class="First"> 6</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Rrule" align="center"><p class="First"> 6</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac Arrest</span></p></td>
<td class="Rrule" align="center"><p class="First"> 6</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Rrule" align="center"><p class="First"> 5</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></p></td>
<td class="Rrule" align="center"><p class="First"> 5</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Rrule" align="center"><p class="First"> 5</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Kidney Failure</span></p></td>
<td class="Rrule" align="center"><p class="First"> 5</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Rrule" align="center"><p class="First"> 5</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></p></td>
<td class="Rrule" align="center"><p class="First"> 5</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td class="Rrule" align="center"><p class="First"> 4</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></p></td>
<td class="Rrule" align="center"><p class="First"> 4</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal Hemorrhage</span></p></td>
<td class="Rrule" align="center"><p class="First"> 4</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></p></td>
<td class="Rrule" align="center"><p class="First"> 4</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Rrule" align="center"><p class="First"> 4</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory Disorder</span></p></td>
<td class="Rrule" align="center"><p class="First"> 4</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></p></td>
<td class="Rrule" align="center"><p class="First"> 3</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 3</p></td>
</tr>
</tbody>
</table>
<p> <span class="Sup">a</span>The causal association between these adverse events and ABELCET<span class="Sup">®</span> is uncertain.</p>
<p>The following adverse events have also been reported in patients using ABELCET<span class="Sup">®</span> in open-label, uncontrolled clinical studies. The causal association between these adverse events and ABELCET<span class="Sup">®</span> is uncertain.</p>
<p><span class="Italics">Body as a whole:</span> <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span> including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span></p>
<p><span class="Italics">Allergic:</span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, anaphylactoid and other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></p>
<p><span class="Italics">Cardiopulmonary:</span> <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> including <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>.</p>
<p><span class="Italics">Dermatological:</span> <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span></p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, cramping, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, veno-occlusive liver disease, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="195856" conceptname="Cholangitis">cholangitis</span>, <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span></p>
<p><span class="Italics">Hematologic:</span> coagulation defects, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> including <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span></p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span>, including bone, muscle, and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pains</span></p>
<p><span class="Italics">Neurologic:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, transient <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, cerebral vascular <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal syndrome</span> and other <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span></p>
<p><span class="Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, decreased renal function, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">renal tubular acidosis</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span></p>
<p><span class="Italics">Serum electrolyte abnormalities:</span> <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span></p>
<p><span class="Italics">Liver function test abnormalities:</span> increased AST, ALT, alkaline phosphatase, LDH</p>
<p><span class="Italics">Renal function test abnormalities:</span> increased BUN</p>
<p><span class="Italics">Other test abnormalities:</span> <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, hyperamylasemia, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span></p>
<p>To report SUSPECTED ADVERSE REACTIONS, contact Sigma-Tau Pharmaceuticals, Inc. at 1-888-393-4584 or by email at drugsafety@sigmatau.com or contact the FDA at 1-800-FDA-1088 or www.fda.gov/safety/medwatch.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_5a9c4d36-e93f-458d-a88c-f35dc178eb94"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Amphotericin B desoxycholate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has been reported to result in cardio-<span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>. Fifteen patients have been reported to have received one or more doses of ABELCET<span class="Sup">®</span> between 7-13 mg/kg. None of these patients had a serious acute reaction to ABELCET<span class="Sup">®</span>. If an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is suspected, discontinue therapy, monitor the patient’s clinical status, and administer supportive therapy as required. ABELCET<span class="Sup">®</span> is not hemodialyzable.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_dcc1eab5-0bea-4dfd-ab68-ac107fb43fd0"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended daily dosage for adults and children is 5 mg/kg given as a single infusion. ABELCET<span class="Sup">®</span> should be administered by intravenous infusion at a rate of 2.5 mg/kg/h. If the infusion time exceeds 2 hours, mix the contents by <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> the infusion bag every 2 hours. </p>
<p>Renal toxicity of ABELCET<span class="Sup">®</span>, as measured by serum creatinine levels, has been shown to be dose dependent. Decisions about dose adjustments should be made only after taking into account the overall clinical condition of the patient.</p>
<p><span class="Bold">Preparation of Admixture for Infusion:</span> Shake the vial gently until there is no evidence of any yellow sediment at the bottom. Withdraw the appropriate dose of ABELCET<span class="Sup">®</span> from the required number of vials into one or more sterile syringes using an 18-gauge needle. Remove the needle from each syringe filled with ABELCET<span class="Sup">®</span> and replace with the 5-micron filter needle supplied with each vial. Each filter needle may be used to filter the contents of up to four 100 mg vials. Insert the filter needle of the syringe into an IV bag containing 5% Dextrose Injection USP, and empty the contents of the syringe into the bag. The final infusion concentration should be 1 mg/mL. For pediatric patients and patients with cardiovascular disease the drug may be diluted with 5% Dextrose Injection to a final infusion concentration of 2 mg/mL. Before infusion, shake the bag until the contents are thoroughly mixed. Do not use the admixture after dilution with 5% Dextrose Injection if there is any evidence of foreign matter. Vials are for single use. Unused material should be discarded. Aseptic technique must be strictly observed throughout handling of ABELCET<span class="Sup">®</span>, since no bacteriostatic agent or preservative is present.</p>
<p>DO NOT DILUTE WITH SALINE SOLUTIONS OR MIX WITH OTHER DRUGS OR ELECTROLYTES as the compatibility of ABELCET<span class="Sup">®</span> with these materials has not been established. An existing intravenous line should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> with 5% Dextrose Injection before infusion of ABELCET<span class="Sup">®</span>, or a separate infusion line should be used. DO NOT USE AN IN-LINE FILTER. </p>
<p>The diluted ready-for-use admixture is stable for up to 48 hours at 2° to 8°C (36° to 46°F) and an additional 6 hours at room temperature.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_d3a2211e-fb85-4aab-9073-c3f3748dd2fd"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Single-use vials along with 5-micron filter needles are individually packaged. </p>
<p>100 mg of ABELCET<span class="Sup">®</span> in 20 mL of suspension NDC 57665-101-41</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_a9a561ed-94d8-4745-8d59-53edd615fdea"></a><a name="section-10.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Prior to admixture, ABELCET<span class="Sup">®</span> should be stored at 2° to 8°C (36° to 46°F) and protected from exposure to light. Do not freeze. ABELCET<span class="Sup">®</span> should be retained in the carton until time of use. </p>
<p>The admixed ABELCET<span class="Sup">®</span> and 5% Dextrose Injection may be stored for up to 48 hours at 2° to 8°C (36° to 46°F) and an additional 6 hours at room temperature. Do not freeze. Any unused material should be discarded.</p>
<p>U.S. Patent Nos. 4,973,465</p>
<p>                            5,616,334</p>
<p>                            6,406,713</p>
<div class="Figure">
<a name="id810"></a><img alt="Sigma-Tau logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5587db37-f21a-4a39-a319-e1077032ced9&amp;name=b0ed110c-f86e-4dd7-87eb-afe9ed042c69-04.jpg">
</div>
<p>Manufactured by: Sigma-Tau PharmaSource, Inc., Indianapolis, IN 46268.</p>
<p>Distributed by: Sigma-Tau Pharmaceuticals Inc., Gaithersburg, MD 20878.</p>
<p>Revised 03/2013</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_4e96628a-97fd-434b-8150-ca74d0c3ca78"></a><a name="section-11"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 57665-101-41</p>
<p>100 mg</p>
<p>ABELCET®</p>
<p>(amphotericin B Lipid Complex Injection)</p>
<p>Lipid </p>
<p>Formulation</p>
<p>For Intravenous Use Only</p>
<p>5 mg/mL</p>
<p>Contents:<br>One 100 mg vial<br>One filter needle</p>
<p>Manufactured by <span class="Bold">Sigma-Tau PharmaSource, Inc.</span><br>Indianapolis, IN 46268</p>
<p>Distributed by <span class="Bold">Sigma-Tau Pharmaceuticals, Inc.</span><br>Gaithersburg, MD 20878</p>
<p>U.S. PATENT NOS. 4,973,465  5,616,334  6,406,713</p>
<p>Lot:<br>Exp:</p>
<p>C-101-41-US-L</p>
<p>Each mL of ABELCET contains:<br>Amphotericin B USP 5 mg<br>L-α-dimyristoylphosphatidylcholine (DMPC)  3.4 mg<br>L-α-dimyristoylphosphatidylglycerol (DMPG) 1.5 mg<br>Sodium Chloride USP 9 mg<br>Water for Injection USP, q.s. 1 mL</p>
<p><span class="Bold">Preparation</span></p>
<p>ABELCET must be added to 5% Dextrose Injection USP before intravenous infusion.<br>See package insert for complete directions.</p>
<p><span class="Bold">Dosage</span></p>
<p>See package insert for dosage and administration information.</p>
<p><span class="Bold">Storage</span></p>
<p>Store between 2° and 8°C (36° to 46° F).<br>Do not freeze. Protect from light. Single-use vial.</p>
<p><span class="Bold">Rx Only.</span></p>
<div class="Figure">
<a name="id868"></a><img alt="Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5587db37-f21a-4a39-a319-e1077032ced9&amp;name=b0ed110c-f86e-4dd7-87eb-afe9ed042c69-05.jpg"><p class="MultiMediaCaption">Carton Label </p>
</div>
<p>Carton Label </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ABELCET 		
					</strong><br><span class="contentTableReg">amphotericin b, dimyristoylphosphatidylcholine, dl- and dimyristoylphosphatidylglycerol, dl- injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57665-101</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMPHOTERICIN B</strong> (AMPHOTERICIN B) </td>
<td class="formItem">AMPHOTERICIN B</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>DIMYRISTOYLPHOSPHATIDYLCHOLINE, DL-</strong> (DIMYRISTOYLPHOSPHATIDYLCHOLINE, DL-) </td>
<td class="formItem">DIMYRISTOYLPHOSPHATIDYLCHOLINE, DL-</td>
<td class="formItem">3.4 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL-</strong> (DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL-) </td>
<td class="formItem">DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL-</td>
<td class="formItem">1.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57665-101-41</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050724</td>
<td class="formItem">10/18/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sigma-Tau Pharmaceuticals, Inc.
							(068301431)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Xellia Pharmaceuticals AS</td>
<td class="formItem"></td>
<td class="formItem">561816174</td>
<td class="formItem">API MANUFACTURE(57665-101)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sigma-Tau Pharmasource, Inc.</td>
<td class="formItem"></td>
<td class="formItem">961822389</td>
<td class="formItem">MANUFACTURE(57665-101)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0b5d86f9-c7c1-483d-913d-8a5865d8fc72</div>
<div>Set id: 5587db37-f21a-4a39-a319-e1077032ced9</div>
<div>Version: 5</div>
<div>Effective Time: 20141205</div>
</div>
</div> <div class="DistributorName">Sigma-Tau Pharmaceuticals, Inc.</div></p>
</body></html>
